NEW YORK (GenomeWeb News) – Affymetrix has confirmed that the unnamed company that it said last week that it had acquired is True Materials, a microparticle technology firm based in the University of California, San Francisco, Mission Bay Campus.
An Affymetrix spokesperson told GenomeWeb Daily News via e-mail that True Materials founder Randy True has joined Affy as a vice president of research and development.
True Materials is developing a digitally encoded microparticle technology that will enable the array manufacturer to enter low to mid-multiplex markets and compete with bead-based platforms. Affy said that the technology is also applicable to the research, applied, and diagnostic markets.
Affy disclosed the acquisition during its second-quarter conference call last week. Steve Fodor, chairman and CEO of the firm, said the technology "is more scalable and cost effective than bead-based approaches." It uses digital microparticles to carry out assays in solution, he said, and is "capable of multiplexing tests ranging up to several thousand markers."